Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • foryvonne
    Junior Member
    • Apr 2011
    • 6

    De novo assembly of highly expressed transcripts

    I am working on a transcriptome project where I have ~400MB-in-length 454 mRNA-seq reads sequenced on a non-normalized cDNA library. I was using mira3 to do de novo assembly of my reads, and it produced a decent assembly over transcripts with a moderate expression level. However, mira has a hard time assembling those highly expressed transcripts (>1000 copies or more). And it's the same thing with cap3. The TIGR assemler (TGICL) offers some ways to deal with highly expressed transcripts, but it doesn't have a great answer either.

    I wonder if anyone has insight of assembling high-expression transcripts? Could de bruijin graph-based assemblers work in this scenario?

    Many thanks,
    Hao
  • Thorondor
    Member
    • Feb 2011
    • 69

    #2
    i also do a de novo assembly of a transcriptome and velvet/oases (de brujin graph-based) works fine especially for highly expressed transcripts. These are especially good assembled when you choose a high kmer.

    Comment

    • sklages
      Senior Member
      • May 2008
      • 628

      #3
      Have you tried Roche's Newbler in cDNA mode?

      Comment

      • foryvonne
        Junior Member
        • Apr 2011
        • 6

        #4
        Originally posted by Thorondor View Post
        i also do a de novo assembly of a transcriptome and velvet/oases (de brujin graph-based) works fine especially for highly expressed transcripts. These are especially good assembled when you choose a high kmer.
        That's great to know. Just to clarify, are velvet/oases working fine too on 454 reads?

        Comment

        • foryvonne
          Junior Member
          • Apr 2011
          • 6

          #5
          Originally posted by sklages View Post
          Have you tried Roche's Newbler in cDNA mode?
          I don't have a copy of Newbler. I emailed Roche for one weeks ago but still waiting for their replies.

          Comment

          • kmcarr
            Senior Member
            • May 2008
            • 1181

            #6
            Originally posted by foryvonne View Post
            I don't have a copy of Newbler. I emailed Roche for one weeks ago but still waiting for their replies.
            Did you just send an e-mail to a general contact address or did you use their online software request form:

            Comment

            • foryvonne
              Junior Member
              • Apr 2011
              • 6

              #7
              I was sending an email. I'll trying sending an request form too. Thanks for letting me know.

              Comment

              • Thorondor
                Member
                • Feb 2011
                • 69

                #8
                Originally posted by foryvonne View Post
                That's great to know. Just to clarify, are velvet/oases working fine too on 454 reads?
                Well it should work fine I guess especially for the high expressed transcripts. But I can't say that for sure since I am working with Illumina reads.

                Comment

                • Jenzo
                  Member
                  • Mar 2011
                  • 31

                  #9
                  Does a non-normalized cDNA library has an impact on number of reads used by the assembler?
                  I'm asking because we're also working with Illumina Reads. We're using Velvet and SOAPdenovo at the moment. Velvet, for example, only uses 15594122 / 87419634 reads. Our reads are (after quality trimming to mean_qual = 20 and min_len = 35) between 35 and 60 bp long, the kmer-value for this assembly was set to 29 and velvet was run in -shortPaired mode. Anyway there are about 330 000 Contigs with N50=106 and 2300 Contigs longer than 500bp with N50=696.
                  Using lower kmer-values decreases the number of contigs, but increases the numer of used reads which is going on with a decrease in N50 value in both, all and long contigs only.
                  Last edited by Jenzo; 05-04-2011, 12:55 AM.

                  Comment

                  • Thorondor
                    Member
                    • Feb 2011
                    • 69

                    #10
                    so what exactly is your question? This sounds all reasonable to me. You have a comparison to a normalized library? What is your expected coverage? And kmer 29 might be bit high if your calculated expected coverage is around 10-20.

                    Comment

                    • Jenzo
                      Member
                      • Mar 2011
                      • 31

                      #11
                      Thanks for reply, Thorondor! We have a normalized library, sequenced with 454 and assembled it using nearly 90% of all reads with Mira. The question is: Why does Velvet use only about 15% of all reads and could it be because of the non-normalisation?
                      Mean Coverage is (according to Velvet's own measurement in contigs.fa) between 21 and 26 for all long Contigs (> 500bp).
                      Perhaps someone can recommend an assembler, which uses more reads on a non-normalized library.

                      Fyi, we did 8 assemblies with Velvet, using the following kmer-values: 21 (-short, for scaffolding with other algorithms using PE-information), 23 (-shortPaired), 23 (-short), 25 (-short), 27 (-shortPaired), 29 (-shortPaired), 31 (-shortPaired), 35 (-short). With k=23, shortPaired, Velvet uses about 25% of all reads, which was the maximum of all assemblies. Because scaffolding with other algorithms increases N50 currently up to 950 we would like to use Velvet only in -short mode, where the number of used reads is low (~11%).
                      Got my question? :-)
                      Last edited by Jenzo; 05-04-2011, 01:21 AM. Reason: error correction

                      Comment

                      • Thorondor
                        Member
                        • Feb 2011
                        • 69

                        #12
                        no, i don't think that the non-normalisation is the reason here, but keep in mind that you coverage is not consistent over all transcripts. So it might get some transcripts better assembled with a setting the exp_cov really high and some better when you really set it to low values, this will influence the amount of reads used.

                        Also try to estimate your expected coverage on your own e.g. (total amount of bp in your reads)/(expected transcriptome size)

                        Are the paired end shuffled correctly into one file after trimming? Some reads are discarded after trimming so did you use select_paired.pl in the contrib-folder of velvet?

                        Since it seems like you do de novo transcriptome assembly why not try oases?

                        Comment

                        • Jenzo
                          Member
                          • Mar 2011
                          • 31

                          #13
                          Dear Thorondor, thanks a lot for this suggestions! I'll try to estimate coverage and then try some values for exp_cov.
                          I'm really sure, that the reads are shuffled correctly, because trimming did not discard reads at all (low quality reads were just a single N after quality trimming) and the filter-on-length-script was wrote by myself, respecting always both reads (/1 and /2) and discarding none or both.
                          And you're right, we're doing de novo transcriptome assembly, but Oases runs out of memory (32 GB RAM). I set up a new virtual machine now, with 32 GB physical and about 60GB in swap and will try to run Oases on velvetg's output. (I already know that it will take a while ^^)
                          Thanks again a lot for help :-)

                          Comment

                          Latest Articles

                          Collapse

                          • SEQadmin2
                            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                            by SEQadmin2


                            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                            The systematic characterization of the human proteome has
                            ...
                            07-20-2026, 11:48 AM
                          • SEQadmin2
                            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                            by SEQadmin2



                            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                            ...
                            07-09-2026, 11:10 AM
                          • SEQadmin2
                            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                            by SEQadmin2



                            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                            07-08-2026, 05:17 AM

                          ad_right_rmr

                          Collapse

                          News

                          Collapse

                          Topics Statistics Last Post
                          Started by SEQadmin2, Yesterday, 11:41 AM
                          0 responses
                          9 views
                          0 reactions
                          Last Post SEQadmin2  
                          Started by SEQadmin2, 07-20-2026, 11:10 AM
                          0 responses
                          23 views
                          0 reactions
                          Last Post SEQadmin2  
                          Started by SEQadmin2, 07-13-2026, 10:26 AM
                          0 responses
                          36 views
                          0 reactions
                          Last Post SEQadmin2  
                          Started by SEQadmin2, 07-09-2026, 10:04 AM
                          0 responses
                          45 views
                          0 reactions
                          Last Post SEQadmin2  
                          Working...